Private biotechnology is showing fresh signs of life. According to a tally by Endpoints News, 40 private biotech companies disclosed funding rounds of $100 million or more in the first half of 2026 — a figure the publication says is higher than the number recorded over the same stretch of 2025.
Endpoints News attributes part of the increase to what it calls a "June flourish," a late-quarter surge in large deals that lifted the six-month total. The trade outlet frames the count as a rebound in biotech "megarounds," the industry shorthand for outsized private financings that typically fund drug development, clinical trials and company expansion.
The $100 million threshold matters because rounds of that size are a rough gauge of how confident investors feel about backing young, still-private drug developers. These companies are usually years away from generating revenue, so they lean heavily on venture capital and other private funding to keep their research programs running. When those checks get bigger and more frequent, it signals that money is flowing back into a sector that had cooled.
Endpoints News reports the comparison strictly against the first half of 2025, and the specific dollar totals and the identities of the companies involved are drawn from its own count rather than an official industry registry. Tallies like this can vary depending on how each outlet defines a "disclosed" round and what timing it uses.
Still, the direction is the notable part. After a prolonged funding slump that forced many biotech firms to cut staff, shelve programs or seek buyers, a rising megaround count suggests capital is returning to early-stage drug research — even if unevenly, with much of the momentum concentrated in a single strong month.
Why it matters: more large private financings can translate into more experimental medicines advancing toward patients, and it hints that investor appetite for risky, long-horizon biotech bets is recovering.